Literature DB >> 9809991

Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens.

L Le Marchand1, L Sivaraman, L Pierce, A Seifried, A Lum, L R Wilkens, A F Lau.   

Abstract

The dramatic shift in the pathological presentation of lung cancer [the proportional decrease in squamous cell carcinoma (SCC) and increase in adenocarcinoma (AC)] observed in the United States after the 1950s may have taken place as the result of the reduction in polycyclic aromatic hydrocarbons (PAHs) and the increase in N-nitrosamines in inhaled smoke from filtered low-yield cigarettes. The predominant mutation patterns of these tumors also suggest differences in their etiology. We tested the hypothesis that genetic susceptibility to PAHs, as determined by polymorphisms in CYP1A1 and GSTM1, predominantly causes lung SCCs, and susceptibility to nitrosamines, as determined by polymorphisms in CYP2E1, predominantly causes lung ACs. CYP1A1 and GSTM1 play a major role in the metabolic activation and detoxification of PAHs, respectively, and CYP2E1 plays a major role in the metabolic activation of nitrosamines. We conducted a population-based case-control study among 341 incident lung cancer cases and 456 controls of Caucasian, Japanese, or Hawaiian origin. In-person interviews collected detailed information on lifestyle risk factors, and DNA extracted from peripheral leukocytes was used in PCR-based genotyping assays. Logistic regression analyses were used to compute odds ratios and 95% confidence intervals (CIs) for each cell type, adjusting for smoking and dietary variables. The presence of at least one copy of the CYP1A1 MspI variant allele was found to be associated with a 2.4-fold (95% CI, 1.2-4.7) increase in the risk of SCC when this gene was considered singly and a 3.1-fold (95% CI, 1.2-7.9) increase in the risk of SCC when combined with a GSTM1 deletion. No significant association was found between MspI and all lung cancers or other cell types or with the CYP1A1 exon 7 polymorphism. In contrast, the CYP2E1 RsaI and DraI polymorphisms were not clearly related to SCC risk, but these homozygous variant genotypes were associated with a 10-fold (95% CI, 0.0-0.5) decrease in the risk of overall lung cancer (RsaI variant) and AC (DraI variant) compared to the homozygous wild-type genotypes. Inverse associations with these two closely linked CYP2E1 polymorphisms were also suggested for small cell carcinoma. In agreement with past experimental and epidemiological data, the associations found in this study between CYP1A1 and lung SCC and between CYP2E1 and lung AC suggest a certain specificity of tobacco smoke PAHs for lung SCC and tobacco-specific nitrosamines for lung ACs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9809991

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

Review 1.  Genetic polymorphism and cancer risk.

Authors:  M L Clapper
Journal:  Curr Oncol Rep       Date:  2000-05       Impact factor: 5.075

2.  Elucidation of CYP2E1 5' regulatory RsaI/Pstl allelic variants and their role in risk for oral cancer.

Authors:  S Liu; J Y Park; S P Schantz; J C Stern; P Lazarus
Journal:  Oral Oncol       Date:  2001-07       Impact factor: 5.337

3.  RUNX3 downregulation in human lung adenocarcinoma is independent of p53, EGFR or KRAS status.

Authors:  Mohd Feroz Mohd Omar; Kosei Ito; Min En Nga; Ross Soo; Bee Keow Peh; Tuty Muliana Ismail; Bhavin Thakkar; Richie Soong; Yoshiaki Ito; Manuel Salto-Tellez
Journal:  Pathol Oncol Res       Date:  2012-06-24       Impact factor: 3.201

4.  Assessment of cumulative evidence for the association between glutathione S-transferase polymorphisms and lung cancer: application of the Venice interim guidelines.

Authors:  Scott M Langevin; John P A Ioannidis; Paolo Vineis; Emanuela Taioli
Journal:  Pharmacogenet Genomics       Date:  2010-10       Impact factor: 2.089

5.  Genetic polymorphism of the CYP1A1, CYP2E1, GSTM1 and GSTT1 genes and lung cancer susceptibility in a north indian population.

Authors:  R C Sobti; S Sharma; A Joshi; S K Jindal; A Janmeja
Journal:  Mol Cell Biochem       Date:  2004-11       Impact factor: 3.396

6.  Differential methylation pattern of xenobiotic metabolizing genes and susceptibility to Balkan endemic nephropathy, in a cohort of Romanian patients.

Authors:  Alexandra Ivan; Dilys Lam; Mirabela Iustina Cristea; Ada Telea; Alexandra Teodora Gruia; Camelia Oprean; Florin Margineanu; Florina Maria Bojin; Richard Saffery; Virgil Paunescu; Calin Adrian Tatu
Journal:  J Nephrol       Date:  2019-06-20       Impact factor: 3.902

7.  Combined CYP1A1/GSTM1 at-risk genotypes are overrepresented in squamous cell lung carcinoma patients but underrepresented in elderly tumor-free subjects.

Authors:  Evgeniya V Belogubova; Yulia M Ulibina; Irina K Suvorova; Ekatherina Sh Kuligina; Maria B Karpova; Vladimir A Shutkin; Andrey V Koloskov; Alexandr P Kuchinskiy; Alexandr V Togo; Kaido P Hanson; Ari Hirvonen; Evgeny N Imyanitov
Journal:  J Cancer Res Clin Oncol       Date:  2006-01-14       Impact factor: 4.553

8.  Evaluation of models for predicting the probability of malignancy in patients with pulmonary nodules.

Authors:  You Li; Hui Hu; Ziwei Wu; Ge Yan; Tangwei Wu; Shuiyi Liu; Weiqun Chen; Zhongxin Lu
Journal:  Biosci Rep       Date:  2020-02-28       Impact factor: 3.840

9.  Combined effects of CYP1A1 MspI and GSTM1 genetic polymorphisms on risk of lung cancer: an updated meta-analysis.

Authors:  Wen Li; Li-Qiang Song; Jian Tan
Journal:  Tumour Biol       Date:  2014-06-18

10.  A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma.

Authors:  Maria Teresa Landi; Nilanjan Chatterjee; Kai Yu; Lynn R Goldin; Alisa M Goldstein; Melissa Rotunno; Lisa Mirabello; Kevin Jacobs; William Wheeler; Meredith Yeager; Andrew W Bergen; Qizhai Li; Dario Consonni; Angela C Pesatori; Sholom Wacholder; Michael Thun; Ryan Diver; Martin Oken; Jarmo Virtamo; Demetrius Albanes; Zhaoming Wang; Laurie Burdette; Kimberly F Doheny; Elizabeth W Pugh; Cathy Laurie; Paul Brennan; Rayjean Hung; Valerie Gaborieau; James D McKay; Mark Lathrop; John McLaughlin; Ying Wang; Ming-Sound Tsao; Margaret R Spitz; Yufei Wang; Hans Krokan; Lars Vatten; Frank Skorpen; Egil Arnesen; Simone Benhamou; Christine Bouchard; Andres Metspalu; Andres Metsapalu; Tonu Vooder; Mari Nelis; Kristian Välk; John K Field; Chu Chen; Gary Goodman; Patrick Sulem; Gudmar Thorleifsson; Thorunn Rafnar; Timothy Eisen; Wiebke Sauter; Albert Rosenberger; Heike Bickeböller; Angela Risch; Jenny Chang-Claude; H Erich Wichmann; Kari Stefansson; Richard Houlston; Christopher I Amos; Joseph F Fraumeni; Sharon A Savage; Pier Alberto Bertazzi; Margaret A Tucker; Stephen Chanock; Neil E Caporaso
Journal:  Am J Hum Genet       Date:  2009-10-15       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.